Immunovant, Inc.

IMVT

$39.12

-0.94%

N/A-$0.37

Healthcare

Biotechnology

NASDAQ

Active Trading

Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of ...

Historical Employee Count of IMVT

Current

315

Change

-12.98%

Minimum

124

Maximum

362

Recent Filings

Report Date	Employees	Form Type	Filing Date	SEC Filing
Mar 31, 2026	315	10-K	May 20, 2026	View
Mar 31, 2025	362	10-K	May 29, 2025	View
Mar 31, 2024	207	10-K	May 29, 2024	View
Mar 31, 2023	164	10-K	May 22, 2023	View
Mar 31, 2022	124	10-K	Jun 8, 2022	View

Supply Chain of IMVT

Upstream / Downstream / Proxies

Upstream

HanAll Biopharma Co., Ltd.KRX:009420 Roivant Sciences Ltd. (Parent Company)NASDAQ:ROIVPrimary CDMO (Clinical Trial Material Manufacturer) - UnconfirmedUnconfirmedContract Research Organization(s) (CROs)UnconfirmedCell Culture Media & Raw Material Suppliers (via CDMOs)UnconfirmedSpecialty Reagent & Antibody Suppliers (via HanAll/Roivant)

Downstream

Phase 2/3 Clinical Trial Sites (Global)Future Commercial Partner (Pre-Commercial Stage)

Proxies

Roivant Sciences Ltd.NASDAQ:ROIV argenx SENASDAQ:ARGX HanAll Biopharma Co., Ltd.KRX:009420UCB S.A.EBR:UCB

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer